108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
乳腺癌循环肿瘤 DNA 的临床管理：检测、预测与监测
Authors Lu Y, Ren L, Yang M, Liu J
Received 25 May 2025
Accepted for publication 19 September 2025
Published 25 September 2025 Volume 2025:17 Pages 851—861
DOI https://doi.org/10.2147/BCTT.S542704
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Pranela Rameshwar
Yongqu Lu,1,* Lehao Ren,2,* Meng Yang,1 Jun Liu1
1Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China; 2Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China
*Yongqu Lu and Lehao Ren contributed equally to this work
Correspondence: Meng Yang, Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China, Email mengyang7012@163.com Jun Liu, Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China, Email docljun@126.com
Abstract: Despite substantial progress in the diagnosis and treatment of breast cancer, current therapeutic regimens exhibit limitations, necessitating the identification of more robust biomarkers to optimize personalized strategies. Circulating tumor DNA (ctDNA), as a non-invasive liquid biopsy modality, overcomes the inherent constraints of biopsies in capturing tumor heterogeneity. Accumulating evidence from prospective cohort studies demonstrates the clinical utility of ctDNA in risk stratification, guidance of therapeutic decision-making, recurrence surveillance and other clinical applications. Furthermore, ctDNA profiling enhances real-time pharmacodynamic monitoring and accelerates drug development by identifying molecular responders. The methodical requirements and challenges inherent in implementing liquid biopsy assessments in the clinic are examined. These encompass critical pre-analytical variables, the need for highly sensitive and specific analytical techniques, standardization of assays and bioinformatics pipelines across laboratories and the complexities of interpreting results. This review synthesizes current evidence supporting ctDNA integration into breast cancer management frameworks and systematically addresses its methodological challenges and clinical limitations.
Keywords: breast cancer, circulating tumor DNA, minimal residual disease, neoadjuvant therapy
1Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China; 2Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China
*Yongqu Lu and Lehao Ren contributed equally to this work
Correspondence: Meng Yang, Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China, Email mengyang7012@163.com Jun Liu, Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China, Email docljun@126.com
Abstract: Despite substantial progress in the diagnosis and treatment of breast cancer, current therapeutic regimens exhibit limitations, necessitating the identification of more robust biomarkers to optimize personalized strategies. Circulating tumor DNA (ctDNA), as a non-invasive liquid biopsy modality, overcomes the inherent constraints of biopsies in capturing tumor heterogeneity. Accumulating evidence from prospective cohort studies demonstrates the clinical utility of ctDNA in risk stratification, guidance of therapeutic decision-making, recurrence surveillance and other clinical applications. Furthermore, ctDNA profiling enhances real-time pharmacodynamic monitoring and accelerates drug development by identifying molecular responders. The methodical requirements and challenges inherent in implementing liquid biopsy assessments in the clinic are examined. These encompass critical pre-analytical variables, the need for highly sensitive and specific analytical techniques, standardization of assays and bioinformatics pipelines across laboratories and the complexities of interpreting results. This review synthesizes current evidence supporting ctDNA integration into breast cancer management frameworks and systematically addresses its methodological challenges and clinical limitations.
Keywords: breast cancer, circulating tumor DNA, minimal residual disease, neoadjuvant therapy